MedTrace Logo

Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects

NCT04920370 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2022-02-11

No results posted yet for this study

Summary

This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALXN1720 administered subcutaneously (SC) or intravenously (IV).

Conditions

  • Healthy

Interventions

DRUG

ALXN1720 SC

ALXN1720 will be administered via SC route.

DRUG

ALXN1720 IV

ALXN1720 will be administered via IV route.

DRUG

rHuPH20

rHuPH20 will be administered via SC route.

DRUG

Placebo SC

Placebo will be administered via SC route.

DRUG

Placebo IV

Placebo will be administered via IV route.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-04
Primary Completion
2021-11-16
Completion
2021-11-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920370 on ClinicalTrials.gov